MX2020012939A - Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios. - Google Patents
Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.Info
- Publication number
- MX2020012939A MX2020012939A MX2020012939A MX2020012939A MX2020012939A MX 2020012939 A MX2020012939 A MX 2020012939A MX 2020012939 A MX2020012939 A MX 2020012939A MX 2020012939 A MX2020012939 A MX 2020012939A MX 2020012939 A MX2020012939 A MX 2020012939A
- Authority
- MX
- Mexico
- Prior art keywords
- immune checkpoint
- checkpoint inhibitor
- suppressing
- malignant tumor
- determination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención está dirigida al problema de proporcionar: un método para identificar un paciente con un tumor maligno en el que se puede esperar que un inhibidor del punto de control inmunológico sea más eficaz; y un agente para suprimir el avance, suprimir la recurrencia y/o tratar un tumor maligno, caracterizado por la prescripción basada en el método. La presente invención proporciona: la determinación de un paciente con un tumor maligno en el que se puede esperar que un inhibidor del punto de control inmune sea más efectivo, tal determinación se realiza analizando los elementos de evaluación que comprenden una combinación de la intensidad de expresión de PD-1 y la proporción de células que expresan PD-1, etc., en las células Treg y las células T CD8+ en el tejido tumoral o la sangre; y un agente para suprimir el avance, suprimir la recurrencia y/o tratar un tumor maligno caracterizado por la prescripción basada en la determinación.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018105017 | 2018-05-31 | ||
JP2018189370 | 2018-10-04 | ||
PCT/JP2019/021633 WO2019230919A1 (ja) | 2018-05-31 | 2019-05-30 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020012939A true MX2020012939A (es) | 2021-02-15 |
Family
ID=68697509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020012939A MX2020012939A (es) | 2018-05-31 | 2019-05-30 | Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210198361A1 (es) |
EP (1) | EP3804758A4 (es) |
JP (1) | JP7388635B2 (es) |
KR (1) | KR20210018253A (es) |
CN (1) | CN112203688A (es) |
AU (1) | AU2019277632A1 (es) |
BR (1) | BR112020024404A2 (es) |
CA (1) | CA3101766A1 (es) |
IL (1) | IL278967A (es) |
MX (1) | MX2020012939A (es) |
PH (1) | PH12020552011A1 (es) |
SG (1) | SG11202011651SA (es) |
TW (1) | TW202015732A (es) |
WO (1) | WO2019230919A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109485727A (zh) * | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
CA3149537A1 (en) * | 2019-08-05 | 2021-02-11 | Ono Pharmaceutical Co., Ltd. | Biomarkers for determining the efficacy of immune checkpoint inhibitors |
WO2022017435A1 (zh) * | 2020-07-22 | 2022-01-27 | 信达生物制药(苏州)有限公司 | 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用 |
EP3944863A1 (en) * | 2020-07-28 | 2022-02-02 | Fundació Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM) | Combined therapy against cancer |
CN113125751B (zh) * | 2021-04-12 | 2022-11-08 | 首都医科大学附属北京世纪坛医院 | 外周血pd-1/pd-l1预测乳腺癌肿瘤组织中pd-l1水平的方法 |
CN114159557A (zh) * | 2021-11-09 | 2022-03-11 | 北京东方百泰生物科技股份有限公司 | 一种治疗肿瘤疾病的联合用药组合物及应用 |
WO2023235839A1 (en) * | 2022-06-02 | 2023-12-07 | Immunext, Inc. | Development of vista-centric tumor immunophenotyping for identification of potential biomarkers for anti-vista therapy |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (es) | 1956-03-21 | 1900-01-01 | ||
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
WO2014194293A1 (en) * | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
AU2014315457B2 (en) | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
BR112016010224A2 (pt) * | 2013-11-05 | 2018-05-02 | Cognate Bioservices, Inc. | combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer. |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
EP3191113B1 (en) | 2014-09-11 | 2019-11-06 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-l1 protein/protein interactions |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
BR112017010101A2 (pt) * | 2014-12-16 | 2018-01-02 | Bristol Myers Squibb Co | uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
SG11201804152RA (en) | 2015-11-19 | 2018-06-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
ES2844374T3 (es) | 2015-12-22 | 2021-07-22 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
EP3452476B1 (en) | 2016-05-06 | 2021-12-15 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10941129B2 (en) | 2016-05-23 | 2021-03-09 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | Benzyl phenyl ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof |
TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
US20180055882A1 (en) * | 2016-08-04 | 2018-03-01 | The Regents Of The University Of California | Functional immunophenotyping of leukocytes in human tissues |
-
2019
- 2019-05-30 CA CA3101766A patent/CA3101766A1/en active Pending
- 2019-05-30 KR KR1020207034437A patent/KR20210018253A/ko unknown
- 2019-05-30 CN CN201980036678.6A patent/CN112203688A/zh active Pending
- 2019-05-30 TW TW108118759A patent/TW202015732A/zh unknown
- 2019-05-30 MX MX2020012939A patent/MX2020012939A/es unknown
- 2019-05-30 US US17/058,794 patent/US20210198361A1/en active Pending
- 2019-05-30 SG SG11202011651SA patent/SG11202011651SA/en unknown
- 2019-05-30 EP EP19812634.4A patent/EP3804758A4/en active Pending
- 2019-05-30 JP JP2020522606A patent/JP7388635B2/ja active Active
- 2019-05-30 BR BR112020024404-0A patent/BR112020024404A2/pt unknown
- 2019-05-30 AU AU2019277632A patent/AU2019277632A1/en not_active Abandoned
- 2019-05-30 WO PCT/JP2019/021633 patent/WO2019230919A1/ja unknown
-
2020
- 2020-11-24 PH PH12020552011A patent/PH12020552011A1/en unknown
- 2020-11-25 IL IL278967A patent/IL278967A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202015732A (zh) | 2020-05-01 |
IL278967A (en) | 2021-01-31 |
KR20210018253A (ko) | 2021-02-17 |
EP3804758A1 (en) | 2021-04-14 |
CA3101766A1 (en) | 2019-12-05 |
CN112203688A (zh) | 2021-01-08 |
EP3804758A4 (en) | 2022-03-02 |
US20210198361A1 (en) | 2021-07-01 |
AU2019277632A1 (en) | 2020-12-24 |
JPWO2019230919A1 (ja) | 2021-07-08 |
SG11202011651SA (en) | 2020-12-30 |
PH12020552011A1 (en) | 2021-06-14 |
BR112020024404A2 (pt) | 2021-03-02 |
JP7388635B2 (ja) | 2023-11-29 |
WO2019230919A1 (ja) | 2019-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012939A (es) | Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios. | |
MX2021007790A (es) | Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
MX2021000100A (es) | Inhibidores de muerte programada-1 (pd-1)/ ligando de muerte programada 1 (pd-l1). | |
MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
AU2017225061B2 (en) | Biomarkers and methods of treating PD-1 and PD-L1 related conditions | |
MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
MX2018006745A (es) | Metodos de tratamiento de neoplasias malignas. | |
MX2019002023A (es) | Usos de inhibidores de pd-1/pd-l1 y/o inhibidores de ctla-4 con un producto biológico que contiene múltiples componentes citocínicos para tratar el cáncer. | |
WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
MX368507B (es) | Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer. | |
MX2023006039A (es) | Celulas inmunes defectuosas para suv39h1. | |
MX2019012192A (es) | Métodos de diagnóstico y terapéuticos para el cáncer. | |
WO2018002640A3 (en) | Methods and compositions for treating cancer with siglec-9 activity modulators | |
PH12017501064A1 (en) | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor | |
TR201811308T4 (tr) | Kanser kok hücrelerini azaltan anti-emp2 tedavisi. | |
MX2019012660A (es) | Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa. | |
MX2021003262A (es) | Metodos de tratamiento. | |
MX2022003396A (es) | Uso de inhibidores de dkk-1 para tratar el cancer. | |
MX2021009247A (es) | Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1. | |
MX2021003265A (es) | Metodos de tratamiento. | |
MX2020011287A (es) | Seleccion de pacientes para terapia con inhibidores de la se?alizacion de la adenosina. | |
PH12019501918A1 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
MX2022003686A (es) | Uso de inhibidores de fgfr en canceres geneticamente alterados para mejorar la respuesta de los pacientes a los inhibidores de puntos de control inmunitarios en entornos de tratamiento secuencial. | |
MX2021015937A (es) | Inhibicion de sirp-gamma para el tratamiento del cancer. |